DEVELOPMENT OF A PROPIDIUM IODIDE FLUORESCENCE ASSAY FOR PROLIFERATION AND CYTOTOXICITY ASSAYS

被引:208
作者
DENGLER, WA [1 ]
SCHULTE, J [1 ]
BERGER, DP [1 ]
MERTELSMANN, R [1 ]
FIEBIG, HH [1 ]
机构
[1] UNIV FREIBURG,MED CTR,DEPT INTERNAL MED 1,D-79106 FREIBURG,GERMANY
关键词
CHEMOSENSITIVITY TESTING; CYTOTOXICITY ASSAY; FLUORESCENCE ASSAY; PROLIFERATION ASSAY; PROPIDIUM IODIDE;
D O I
10.1097/00001813-199508000-00005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A propidium iodide fluorescence assay (PIA) was developed to characterize the in vitro growth of human tumor cell lines as well as to test the cytotoxic activity of standard compounds. Propidium iodide (PI) was used as a dye which penetrates only damaged cellular membranes. Intercalation complexes are formed by PI with double-stranded DNA which effect an amplification of the fluorescence. Incubation of the total cell population with PI end subsequent fluorescence detection allowed assessment of the number of non-vital cells (first measurement). After freezing the cells at -20 degrees C for 24 h PI had access to total DNA leading to total cell population counts (second measurement). The number of viable cells was calculated by the difference between these two measurements, In the proliferation and cytotoxicity assays 5 x 10(3) cells per well were plated in 96 multiwells and finally stained with 50 mu g/ml PI in 25 mu l for 10 min. A correlation between the log of cell number and the log of flurorescence units could be demonstrated over a 2.5-3 log range (r = 0.97). The lower limit of cell detection was 150-500 cells/wells. In cytotoxicity assays eight clinically used cytostatics were tested which effected a clear dose-response relationship (r = 0.93-0.98) and high reproducibility (r = 0.92). In conclusion, this assay is a simple and rapid test system, the main advantages are the absence of any washing steps and the small number of tumor cells necessary for drug testing. The PIA can easily be used for cell number determinations in biological and pharmacological studies.
引用
收藏
页码:522 / 532
页数:11
相关论文
共 29 条
[1]  
BENDER K, 1992, CONTR ONCOL, V42, P87
[2]   THE CLONOGENIC-ASSAY WITH HUMAN TUMOR XENOGRAFTS - EVALUATION, PREDICTIVE VALUE AND APPLICATION FOR DRUG SCREENING [J].
BERGER, DP ;
HENSS, H ;
WINTERHALTER, BR ;
FIEBIG, HH .
ANNALS OF ONCOLOGY, 1990, 1 (05) :333-341
[3]   STANDARDIZED KINETIC MICROASSAY TO QUANTIFY DIFFERENTIAL CHEMOSENSITIVITY ON THE BASIS OF PROLIFERATIVE ACTIVITY [J].
BERNHARDT, G ;
REILE, H ;
BIRNBOCK, H ;
SPRUSS, T ;
SCHOENENBERGER, H .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1992, 118 (01) :35-43
[4]  
CARMICHAEL J, 1987, CANCER RES, V47, P936
[5]  
Carney D N, 1985, Important Adv Oncol, P78
[6]  
COURTENAY VD, 1978, BRIT J CANCER, V37, P264
[7]  
EDDIN M, 1970, J IMMUNOL, V104, P1303
[8]  
FIEBIG HH, 1992, CONTR ONCOL, V42, P321
[9]   COLONY ASSAY WITH HUMAN-TUMOR XENOGRAFTS, MURINE TUMORS AND HUMAN-BONE MARROW - POTENTIAL FOR ANTICANCER DRUG DEVELOPMENT [J].
FIEBIG, HH ;
SCHMID, JR ;
BIESER, W ;
HENSS, H ;
LOHR, GW .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (07) :937-948
[10]  
FRESHNEY RI, 1975, BRIT J CANCER, V31, P89, DOI 10.1038/bjc.1975.11